FDA Approves New Drug for Rare Blood Cancer
The US FDA has approved Takeda and Protagonist Therapeutics' new drug to treat polycythemia vera, a rare blood cancer. The treatment offers a less-invasive alternative to frequent bloodletting procedures for thousands of patients.
Xurve View
Insights:
Xurve View
TAKEDA PHARMACEUTICAL CO LTD and PROTAGONIST THERAPEUTICS INC secured United States health regulator approval for rusfertide, a first-of-its-kind treatment for a rare blood cancer. The drug brings a less-invasive option for patients in the United States who have relied on frequent bloodletting procedures. The therapy targets polycythemia vera, a slow-growing cancer affecting 90,000 Americans that causes bone marrow to overproduce red blood cells.
